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Abstract
Background: Neurologic toxicities with immune therapy are rare, but can cause devastating and often permanent
injury when they occur. Although there is increasing interest in the potential synergism between immune therapy
and radiation, it is possible that such combinations may lead to a greater number or increased severity of immune-
related adverse events. We present here a case of extensive and progressive transverse myelitis following combined
therapy, which did not improve until treatment with infliximab. This case highlights the unmet need for treatment
of adverse events that are refractory to consensus recommendations, and may ultimately require further study and
incorporation into future published guidelines.
Case presentation: We report a case of a 68-year-old with metastatic melanoma, who developed transverse
myelitis in the setting of immune checkpoint blockade and spinal irradiation for vertebral metastases. Despite
management according to published consensus guidelines: cessation of immune therapy, high-dose steroids, and
plasmapheresis, he continued to deteriorate neurologically, and imaging revealed a progressive and ascending
transverse myelitis. The patient was then treated with infliximab, and demonstrated dramatic imaging and modest
clinical improvement following the first treatment cycle.
Conclusions: This is the first report describing the successful use of infliximab in immune therapy and radiation-
related transverse myelitis that was not responding to recommended therapy. Evaluation of additional treatment
options such as infliximab for high-grade immune-related neurologic toxicities is warranted, and may be needed
earlier in the disease process to prevent significant morbidity. The adverse effects of immune therapy when used in
combination with radiation also require further investigation.
Keywords: Transverse myelitis, Infliximab, Immune-related adverse events, Checkpoint inhibitor, Radiation
Background
Immune checkpoint inhibitors (ICIs) have revolutionized
cancer treatment, producing durable responses in both
skin and solid organ malignancies [1]. The currently
approved ICIs are monoclonal antibodies targeting the
programmed death protein-1 (PD-1) or the cytotoxic-T-
lymphocyte-antigen-4 (CTLA-4) [2] pathways which
normally limit immune responses. With this shift in the
natural balance of the immune system toward its ef-
fector arm, immune-related adverse effects are to be ex-
pected. Indeed, immune-related toxicities have been
demonstrated in nearly every organ system. For severe
toxicities (grade 3 or higher according to the Common
Terminology Criteria for Adverse Events of the National
Cancer Institute), current guidelines suggest manage-
ment escalation in the following order: ICI cessation,
high-dose steroids, other T cell suppressive medications
and intravenous immunoglobulin (IVIG) or plasmapher-
esis [3–5]. In many organ systems, toxicities unrespon-
sive to standard management have also been shown to
benefit from immunosuppressive drugs such as toci-
lizumab and infliximab [6]. Tocilizumab may lead to
resolution of ICI-induced cytokine release syndrome [7],
arthritis [8], pneumonitis [9], and myocarditis [10].
Infliximab has demonstrated benefit in management of
immunotherapy-induced colitis [11, 12] and scleritis
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[13]. It is unclear if the combination of radiation with
ICIs contributes to additional immune related adverse
events, although small studies of either systemic or
intracranial radiation with ICIs did not report increased
toxicity [14, 15].
High-grade central and peripheral nervous system
toxicity from ICIs is rare and occurs most commonly in
the form of encephalopathies, meningoradiculoneuritis,
Guillain-Barre like syndromes, and myasthenic syn-
dromes [16]. Not only are neurologic toxicities rare, but
their management when refractory to standard treat-
ment is based on limited reports. Here, we describe a
patient who developed transverse myelitis in the setting
of ICI therapy and vertebral radiation for metastatic
melanoma. His transverse myelitis failed to resolve with
standard treatment outlined in published guidelines. In
this case report, administration of infliximab produced
both clinical and imaging improvement.
Case presentation
A man in his late 60s with a history of Stage I melanoma
of the upper thigh, for which he had undergone wide
local excision and negative sentinel lymph node biopsy 2
years prior, presented with new metastatic disease. On
imaging, he was found to have lesions of the lung, liver,
vertebrae, and brain. Fine needle aspiration of a thoracic
lymph node confirmed metastatic melanoma. Next
generation sequencing was notable for BRAF V600E
mutation.
The patient started treatment with combination ipili-
mumab and nivolumab. While undergoing immunother-
apy, the patient also received radiation to his T7-T10
vertebral metastases (30 Gray (Gy) in 10 fractions) and
had stereotactic radiosurgery (SRS) to 16 brain metasta-
ses. Spinal irradiation was performed with a 3D con-
formal technique using opposed anterior-posterior/
posterior-anterior fields. The maximum dose to the
spinal canal was 33.5 Gy.
Magnetic resonance imaging (MRI) of the brain follow-
ing SRS showed marked treatment response. Re-staging
computed tomography (CT) of the chest, abdomen, and
pelvis, performed 2 months after his initial staging scans,
also showed major systemic response. Prior to starting his
fourth cycle of ipilimumab and nivolumab, the patient
noted the onset of intermittent numbness and tingling of
the soles of his feet, with gradual ascension to his knees
over the next 2 months.
MRI brain 1 month later showed a new punctate cere-
bellar metastasis, which was treated using SRS. Positron
emission tomography (PET)/CT demonstrated reso-
lution of numerous hyper-metabolic lesions with a
remaining area of increased focal uptake in the left is-
chial tuberosity (Fig. 1). Given evidence of disease pro-
gression in the ischial tuberosity but not other systemic
areas, the patient transitioned to pembrolizumab and
received radiation to his ischial lesion. Approximately 2
weeks after starting pembrolizumab, the patient noted
gait instability and ataxia, and further ascension of
numbness to the level of his hips. At that time, he was
still able to ambulate independently with the assistance
of walking sticks. One month after starting pembrolizu-
mab, the patient presented to the emergency department
(ED) with 1 day of urinary retention and fecal incontin-
ence. A spinal MRI was performed which showed T2
signal abnormality and patchy enhancement in the thor-
acic spinal cord (T5 to T10) concerning for myelitis or
radiation necrosis without evidence of tumor or malig-
nant cord compression. The T2 signal abnormality
corresponded with the thoracic spinal radiation field
(Fig. 2). Given that the lesion was enhancing and initially
confined to the radiation field, radiation necrosis was
favored at that time.
The patient’s immunotherapy was discontinued, ste-
roids (dexamethasone 8 mg twice daily) were initiated,
and two doses of bevacizumab (for possible radiation
necrosis) were administered, without improvement.
Lumbar puncture was deferred due to recent bevacizu-
mab. Given the lack of improvement to optimal therapy
for radiation necrosis, transverse myelitis was then
favored. Results of serologic evaluation of metabolic
(vitamin B12, thyroid stimulating hormone), infectious
(human immunodeficiency virus, rapid plasma reagin),
and autoimmune (anti-nuclear antibodies, anti-Ro/La,
aquaporin-4 immunoglobulin G, erythrocyte sedimenta-
tion rate, C-reactive protein) etiologies of transverse mye-
litis were normal. The patient was trialed on high-dose
intravenous methylprednisolone (1000mg daily for 5 days)
Fig. 1 Coronal positron emission tomography images of patient
before (a) and 5months after (b) initiation of ICI demonstrating
complete resolution of widespread hypermetabolic lesions in the
lungs, liver, skeleton and mediastinum with the exception of a
residual lesion in the left ischium
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for transverse myelitis. His lower extremity numbness and
gait instability progressed and he started plasmapheresis.
Following 15 sessions of plamapheresis, a dose of
cyclophosphamide 1000mg/m2 was added but the pa-
tient continued to decline with worsening urinary reten-
tion, bilateral lower extremity spasticity, and complete
loss of lower extremity sensation to T5. He did not have
upper extremity involvement. Cerebrospinal fluid (CSF)
analysis at that time was remarkable for elevated protein
(total protein, 99 mg/dL; institutional normal range, 15–
45mg/dL) and negative for malignant cells. Myelin basic
protein was elevated at 31.6 ng/mL (normal < 5.5), and
oligoclonal bands were matched in the serum and CSF,
consistent with an ongoing systemic immune reaction.
CSF albumin index was mildly elevated, suggestive of
slight impairment of the blood-CSF barrier. Serum studies
for antibodies to human T-lymphotropic virus (HTLV) I
and II, and a paraneoplastic panel (anti-NR1, anti-GAD65,
anti-alpha 3AChR, anti-LGI1, anti-VGCC, anti-VGKC,
anti-CASPR2, anti-amphiphysin, anti-CV2, anti-Hu, anti-
Ma, anti-Ta, anti-recoverin, anti-Ri, anti-Yo, anti-Zic4)
were negative. A serum IL-6 level was normal. A serum
TNF-alpha level was not obtained. MRI of the brain dem-
onstrated two new intracranial metastases. MRI of the
spine showed progression of transverse myelitis from T3
to T11 (Fig. 3c), now clearly outside the radiation field.
Body PET/CT revealed worsening osseous metastatic
lesions; therefore the patient began dabrafenib and trame-
tinib. Given his ascending transverse myelitis despite opti-
mal therapy other options including tocilizumab and
infliximab were considered. Based on the low IL-6 level,
the patient was started on infliximab. Spinal MRI 3 weeks
after the first dose of infliximab showed a dramatic reduc-
tion of the level of the T2 cord signal abnormality back to
Fig. 2 Sagittal images of the (a) radiation treatment fields used for palliative spinal radiation extending from thoracic vertebral level T7-T10 and
(b) follow-up spinal MRI obtained 6months after radiation therapy showing T2 signal abnormality (white arrows) within the region of previous
radiation therapy. The dark blue, yellow, and cyan lines in panel A correspond to the 95, 100, 105% isodose lines, respectively
Fig. 3 T2-weighted sagittal MRI images of thoracic spine. The 7th thoracic vertebrae is marked for reference. Arrow indicates the superior border
of the transverse myelitis. a before initiation of therapy, no intrinsic spinal cord lesion. b 6 months after radiation, with cord changes around T7.
c 11 months after radiation, with progressive symptoms and ascending transverse myelitis despite therapy. d Three weeks after initiation of
infliximab, with significant improvement. e. Two months after infliximab, still with some cord abnormality around T7
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T6 to T10 (Fig. 3d) with corresponding improvement in
sensory level and muscle spasms. Continued treatment
with infliximab led to additional incremental gains on
imaging but without further clinical improvement. He
subsequently developed systemic progression on dabrafe-
nib and tremetinib (but with stable central nervous system
disease) and ultimately succumbed to his disease.
Discussion and conclusions
We describe a patient with metastatic melanoma who
developed progressive transverse myelitis following com-
bination therapy with ICIs and spinal irradiation. His
sensory symptoms first manifested approximately 3
months after starting ipilimumab/nivolumab and radi-
ation therapy, and acutely worsened when he was transi-
tioned to pembrolizumab. Our patient was unresponsive
to the standard of care recommended by several consen-
sus groups (discontinuation of immunotherapy, high
dose steroids, and extensive plasmapheresis treatments),
but demonstrated modest clinical and significant im-
aging improvement with infliximab. To our knowledge,
this case represents the first report of successful treat-
ment of ICI-induced transverse myelitis with infliximab.
While most cases can be managed with the discontinu-
ation of immunotherapy and steroids, the optimal steroid
dosing for transverse myelitis and immunotherapy-related
toxicities has not been prospectively defined. Per the
American Academy of Neurology guidelines, the recom-
mended dose and duration of steroids for TM is 1 g IV
methylprednisolone daily for 3 to 7 days [17]. The Na-
tional Comprehensive Cancer Network guidelines for
immunotherapy-related transverse myelitis suggest at least
2mg/kg/day of methylprednisolone and to strongly con-
sider 1 g daily for 3–5 days. The next recommended steps
for unresponsive cases are IVIG or plasmapheresis. There
is no consensus on how to proceed following the failure of
plasmapheresis. A recent case of ICI-related encephalitis
also showed durable response to infliximab [18]. That
case, along with the case presented here, suggest that
infliximab may be beneficial for refractory cases of neuro-
logic ICI adverse events.
Causality is particularly challenging to attribute in this
case because the patient received immunotherapy and
radiation treatment concurrently, and the area of in-
volvement starts within the radiation field. Several
features suggest a combined effect of radiation and im-
mune therapy. First, the dose of radiation that this
patient received (30 Gy in 10 fractions) is well below the
tolerance dose of the spinal cord and highly unlikely to
cause myelopathy in isolation [19–21]. Second, the time
course of his symptom progression is inconsistent with
classically described forms of spinal cord radiation tox-
icity, which is typically a late complication that develops
more than 6months following RT [22]. Third, the acute
worsening of his symptoms 2 weeks after starting pem-
brolizumab and the extension outside the radiation field
further suggests an autoimmune contribution. Lastly,
lack of improvement with bevacizumab, which has been
shown to be helpful in radiation-induced myelitis, versus
response to infliximab is consistent with a component of
immune dysregulation.
Thus, the development of a spinal cord lesion of this
severity was likely the consequence of the combined im-
pact of RT and immunotherapy. Immune therapy can
lead to adverse autoimmune complications, but typically
responds to discontinuing the offending agent, steroids
and plasmapheresis. The intensity of the reaction in our
patient provides caution in applying overlapping therap-
ies of radiation and immune modulation. As more pa-
tients receive combined radiation and immunotherapy,
clinicians must be vigilant for adverse events, and may
need additional therapies such as infliximab early in the
disease process for patients not responding to steroids,
IVIG or plasmapheresis, in order to prevent significant
toxicity.
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